Direct access to fully validated chromatographic assay pipelines, high-potency harvest analytics, preclinical safety evaluation models, and pilot-to-commercial extraction frameworks.
De-risking natural ingredient commercialization through rigorous chromatographic fingerprinting, targeted molecular purification, and systematic pharmacokinetics.
In modern phytochemical supply chains, OEM natural ingredient manufacturers face profound structural challenges. Unlike single-molecule synthetic APIs, raw botanical biomass inherently fluctuates in phytochemical yield due to seasonal variations, soil microbiomes, geo-climatic stressors, and phenotypic variance. For pharmaceutical innovators and clean-label nutraceutical conglomerates, these variabilities cause unacceptable batch-to-batch inconsistencies, bioavailability fluctuations, and regulatory non-compliance.
MedGence (Yineng Pharma) resolves these macro vulnerabilities by merging traditional botanical wisdom with high-resolution analytical chromatography and scalable continuous extraction. Rather than relying on simple extract ratios (e.g., 10:1 or 20:1) that obscure real active marker density, our technical infrastructure establishes absolute stoichiometric quantification. We isolate, identify, and standardize active alkaloids, triterpenoid saponins, flavonoids, and therapeutic polysaccharides to guaranteed potency thresholds, ensuring complete reproducibility across pilot scale and multi-ton industrial outputs.
Employing multi-wavelength HPLC-DAD, tandem mass spectrometry (LC-MS/MS), and HPTLC fingerprint overlays to systematically identify synthetic adulterants, undeclared carrier spikes, and species-level substitution in global botanical shipments.
Optimized low-temperature, subcritical fluid, and superheated liquid solvent recovery cascades minimize thermolabile degradation while slashing organic solvent residue to strict sub-ppm levels conforming to USP <467> and Ph. Eur. limits.
Dedicated contract manufacturing and entrusted CRO execution strictly partition customer proprietary formulas, unique fractionation routes, and proprietary carrier technologies behind ironclad NDAs and air-gapped data architecture.
Navigating complex international botanical compliance through pre-formulated validation packages, ICH-aligned toxicology portfolios, and DMF technical dossiers.
Procuring natural active ingredients requires adherence to divergent regional legal definitions. While the United States regulates botanical extracts largely under Dietary Supplement cGMPs (21 CFR Part 111) and the Botanical Drug Guidance (21 CFR Part 314), the European Union mandates rigorous EFSA Novel Food evaluations or EMA Committee on Herbal Medicinal Products (HMPC) monographs. Simultaneously, Australia's Therapeutic Goods Administration (TGA) exercises stringent listed/registered medicine controls.
Our operational framework bridges these divergent regulatory environments. By providing complete documentation—encompassing residual pesticide screenings (USP <561> / EP 2.8.13 across 400+ compounds), heavy metal limits (ICP-MS testing for Pb, Cd, As, Hg), mycotoxin profiles (Aflatoxin B1/B2/G1/G2 and Ochratoxin A), and microbial testing (USP <61/62>)—we furnish seamless validation dossiers ready for instant inclusion in client submissions worldwide.
Comprehensive Chemistry, Manufacturing, and Controls (CMC) packages detailing stability studies under ICH Q1A(R2) conditions (accelerated and long-term), solvent recovery limits, and active marker validation.
Proven track record with 56 registered TCM hospital preparations in China, demonstrating end-to-end capabilities from clinical safety trials to licensed pilot production and formal hospital-formulary inclusion.
Stringent supplier qualification across China's geo-authentic (Daodi) cultivation bases, verifying species identity via molecular DNA barcoding and seasonal harvest timing to lock in maximum biological potency.
From single compound discovery assays to multi-ton commercial batch production, explore our full spectrum of contract research and contract manufacturing solutions.
Targeted bio-affinity ultrafiltration, cellular target fishing, and spectroscopic fractionation isolating high-affinity secondary metabolites from complex herbal decoctions.
Quantifying seasonal variations and terroir factors across diverse harvest windows to pinpoint the exact harvest date and botanical parts with optimum active metabolite concentration.
Developing and validating high-performance liquid chromatography (HPLC-UV/RID/ELSD), gas chromatography (GC-MS), and HPTLC fingerprint assays compliant with ICH Q2(R1).
Refining extraction temperature, solvent-to-material ratios, macroporous adsorption resin elution gradients, and spray/vacuum freeze-drying parameters to maximize industrial yields.
Resolving hygroscopicity, oxidation, precipitation, and insolubility challenges to protect fragile botanical actives inside downstream tablet, capsule, and liquid matrices.
Delivering acute oral toxicity (LD50), sub-chronic 90-day repeat dose regimens, Ames bacterial reverse mutation, and micronucleus genotoxicity safety data packages.
Cell line culture, enzyme inhibition models (e.g., alpha-glucosidase, PDE5, COX-2, 5-LOX), and reactive oxygen species (ROS) quenching assays substantiating mode-of-action.
Validated disease models covering metabolic syndrome, neurodegenerative decline, inflammatory arthritis, and immunomodulation validating in vivo bioavailability and pharmacodynamics.
GCP-compliant human randomized double-blind placebo-controlled trials (RCTs) providing clinical endpoint evidence essential for New Drug Applications (NDAs) or substantiated health claims.
Leveraging multi-herb TCM compatibility logic to engineer modern multi-target synergistic formulations with superior potency compared to isolated monotherapies.
Direct supply of standardized concentrated liquids, crystallites, lyophilized powders, and volatile essential oils manufactured within state-of-the-art cGMP facilities.
Full-service CDMO manufacturing for oral liquids, two-piece hard gelatin/HPMC capsules, hermetic softgels, micro-tablets, effervescent granules, and functional sachets.
Delivering tailored ingredient architectures matched precisely to formulation requirements, pharmacokinetic goals, and consumer sensory expectations.
Primary Requirements: Absolute single-marker purity (>98%), verified pharmacokinetic clearance profiles, batch-to-batch chemical fingerprint similarity (>0.98), and total compliance with ICH Q3A/B impurity guidelines.
Formats: Highly purified crystalline powders, pharmaceutical lyophilized cakes, standardized active fractions.
Primary Requirements: High-density bioactive concentration, superior water solubility or micro-encapsulated dispersion, non-GMO status, allergen-free processing, and clinical evidence substantiating retail label claims.
Formats: Free-flowing spray-dried extract powders, beadlets, oil suspensions, cold-water dispersible emulsions.
Primary Requirements: Low odor, pale color profiles that do not discolor emulsions, proven transdermal penetrative capacity, non-irritant cytotoxicity ratings (HET-CAM testing), and documented anti-tyrosinase or anti-collagenase efficacy.
Formats: Clarified hydrophilic liquids, liposomal encapsulation pastes, deodorized botanical oils.
Pioneering the next decade of botanical manufacturing through deep learning molecular docking, multi-omics metabolic mapping, and continuous bioprocessing.
Leveraging neural-network-driven virtual screening of hundreds of thousands of historical botanical batches to map ligand interactions between multi-target plant compounds and target human receptor complexes.
Integrating metabolomics, transcriptomics, and high-throughput chromatographic signatures to predict clinical efficacy before animal models commence, cutting exploratory lead times by over 60%.
Replacing traditional batch tanks with continuous flow tubular micro-reactors, ultra-high-pressure membrane filtration, and automated counter-current chromatography for zero-waste production.
Over 100 industrial manufacturers, multinational brand owners, and research hospitals depend on MedGence (Yineng Pharma) for verified botanical science.
Clear answers addressing analytical validation, audit compliance, MOQ scalabilities, and international regulatory handoffs.
Explore our full array of contract research and manufacturing capabilities to initiate your proprietary custom botanical development pipeline.
